Approximately 53,000 cases of oral and oropharyngeal cancer are diagnosed in the United States each year. Men are twice as likely to develop the disease, and it typically affects people older than 55.  

Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

Colorectal cancer (CRC) is the third most common cancer affecting men and women in the United States. When CRC is found at an early stage before it has spread, the five-year relative survival rate is about 90%, yet it remains a leading cause of cancer-related death among both genders. 

Although most cancers contain four to five driver mutations, those drivers remain unknown for about 5% of cancers, according to results of a series of studies examining genomes from 38 different cancer types. The international Pan-Cancer Analysis of Whole Genomes Consortium reported the findings in a collection of 23 articles published in Nature and other affiliated journals.

Modest differences may exist among women with diabetes compared to healthy controls when it comes to adhering to screening recommendations for breast, cervical, and colorectal cancers, according to results of a study published in Diabetologia.

Participation in clinician and patient conversations about lung cancer screening—as well as the actual screening itself—is relatively low. According to one study, only 3.9% of screening-
eligible patients had undergone lung cancer screening. Because the screening recommendations are newer, most patients are unaware that they exist, and research highlights that only 10%–12% of the patient population has had conversations with their clinicians about it.

Even though its incidence is less common, ovarian cancer is the fifth leading cause of death from cancer in women, according to the American Cancer Society. It also estimated more than 22,000 new cases of ovarian cancer in 2019, with a five-year survival of 47% for all stages.

Identifying a panel of tumor-associated antigens and autoantibodies through a simple blood test may one day help providers diagnose the earliest stages of breast cancer, before clinical signs appear.

As an industry standard, the National Comprehensive Cancer Network (NCCN) screening guidelines have served a huge role in cancer prevention and early detection efforts, helping providers identify diagnoses early and give patients their best possible chance at survival. Ensuring screening guidelines are up to date and using the best available evidence is an ongoing process that requires an interprofessional approach.

Although society still hopes for that one big discovery to cure cancer, clinicians know that there’s already a tried and true method to give patients their best shot at survival: catching a diagnosis early or preventing one altogether.

One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

As the leading cause of cancer death in the United States, lung cancer is pervasive and deadly. But like many cancers, patients have a better chance at successful treatment outcomes and survival if caught early through screening and early detection efforts. Despite lung cancer being the second most diagnosed cancer for men and women, not all Americans are aware of its screening recommendations. To address the gap in awareness, the Centers for Disease Control and Prevention (CDC) is promoting a new public health campaign on the issue.

A blood test evaluating several biomarkers was able to reduce the number of lung cancers detected at later stages, according to study results presented at the 2019 World Conference on Lung Cancer.

Precision medicine has a been a hot topic in health care for years now, but costs and coverage issues have created challenges to get patients the genetic testing they need at an affordable cost. In a memo from October 29, 2019, the Centers for Medicare and Medicaid Services (CMS) proposed extending Medicare coverage to pay for genetic sequencing tests for certain hereditary types of ovarian and breast cancer.

In June 2019, in honor of Men’s Health Month, a group of Georgetown nurses, oncology specialists, and professionals from other concentrations volunteered for ONS at the annual Men’s Health Network Congressional Health Screening on Capitol Hill. It was an experience that I will never forget. To be in the offices of the U.S. Congress and to meet elected officials and their staff was incredible, but being able to do what nurses do best—act as the most trusted healthcare professional for patients—was wonderful.

As we reflect on the progress we’ve made to prevent and control cancer and focus on strategies that will help build on those efforts, one thing is certain: We’ve learned a lot about cancer, but we still have much to learn. Adopting healthy lifestyle habits and knowing your family’s history, especially as you get older, can help you lower a patient’s—or nurse’s—chance of getting cancer.

The National Institutes of Health’s (NIH’s) mission is to enhance health and reduce illness throughout the country. Cancer, as the second leading cause of death in the United States, tops the list of diseases on which NIH is focused. Understanding the impact of health disparities, NIH has effectively widened its reach to touch more underserved communities with new prevention efforts.

Not that long ago, women were told to get a Pap test every year. And most of us did, even though it wasn’t always clear why we were being tested. We just did what we were told and thought it was a surefire way to stay healthy. But times and recommendations have changed about what test to have, how often to have it, and the reason to have it. 

Targeted to healthcare providers, the Centers for Disease Control and Prevention (CDC) has released a new public service health campaign to call attention to the importance of regular screenings for breast, cervical, and colorectal cancers. The Screen Out Cancer campaign is designed to raise awareness to ensure that patients and providers know that prevention begins with knowledge.

Pap tests have long been the gold standard to screen women for cervical cancer, but a new study published in JAMA says that in women older than 30 years, HPV testing is less invasive and more accurate.  

Researchers have developed two new gene-based tests that detect DNA mutations that lead to bladder, endometrial, and ovarian cancers. The tests, which are not yet U.S. Food and Drug Administration approved, could be used to identify a new or relapsed cancer earlier, when it is easier to treat.

Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-dose Helical Computed Tomography?

A. Is a current or former smoker

B. Is 55–74 years old

C. Has a 10–20 pack-year history

D. Has a 30 pack-year history but no signs or symptoms of lung cancer 

Of cancers affecting both men and women, colorectal cancer (CRC) is the second leading killer in the United States. In 2014, according to the Centers for Disease Control and Prevention, 139,992 people in the United States were diagnosed with CRC and 51,651 people died from it. Oncology nurses know that screening tests allow for healthcare providers to remove polyps before they become cancer or identify CRC in its earliest, most treatable stages. Clearly, screening is key to preventing CRC, most insurance plans cover screening, and patients now have more screening test options than ever. So why is CRC still so common? Why do people we know and care about still get this disease?

A new three-in-one blood test that analyzes cancer DNA in the bloodstream before and during treatment will allow providers to understand and track which patients are likely to benefit from treatment with olaparib, a PARP inhibitor. Additionally, researchers found which genetic mutations prostate cancers use to resist treatment with olaparib. The study was published in Cancer Discovery.

I have the privilege of managing and being the sole provider in a unique program. I work in the Hereditary Cancer Program at Saint Louis University Cancer Center, where I provide risk assessment services and education about genetic testing to individuals and families in the region. It’s an amazing nursing role, and I can truly help people prevent cancer and manage their risk.

BRCA gene testing is on the rise for women who do not meet the referral requirements based on family history, researchers reported in study findings published in the American Journal of Preventive Medicine. At the same time, many high-risk women do not obtain the test and remain unidentified.

Alongside congressional representatives Debbie Wasserman Schultz and Susan Brooks, ONS and other organizations are lobbying for support of the Protecting Access to Lifesaving Screenings (PALS) Act. This legislation would push insurance companies—along with the Veterans Health Administration—to provide access and coverage to breast cancer screenings for women aged 40–49.

Researchers at Johns Hopkins Kimmel Cancer Center have demonstrated that random, unpredictable DNA copying mistakes account for nearly two-thirds of the mutations that cause cancer. The results were reported in Science.

Despite U.S. Preventive Services Task Force (USPSTF) recommendations, screening rates for smokers at high risk for lung cancer remain very low, according to the findings from a new study published in JAMA Oncology.
 

The U.S. Preventive Services Task Force (USPSTF) has issued new draft revisions for prostate cancer screening guidelines. In the draft, the USPSTF has changed its previous stance on prostate-specific antigen (PSA) screening tests for men aged 55–69. The drafted guidelines now recommend PSA screening tests for men aged 55–69 based on individual assessment. The USPSTF has upgraded its recommendation from D to C, encouraging physicians to discuss with their patients whether PSA testing is right for them. The USPSTF still recommends against PSA screening tests in patients aged 70 or older.

Although overall rates of colorectal cancer have been falling since the 1970s and ‘80s, incidence of the disease has been increasing dramatically in patients younger than 50 years, according to the results of a new study published in the Journal of the National Cancer Institute.

Researchers conducting the largest study to date on screening mammography outcomes have found no evidence to support stopping mammography screenings at a certain age. The findings were presented at the 2016 Radiological Society of North America annual meeting.